[go: up one dir, main page]

NO20090554L - Farmasoytiske preparater av memantin - Google Patents

Farmasoytiske preparater av memantin

Info

Publication number
NO20090554L
NO20090554L NO20090554A NO20090554A NO20090554L NO 20090554 L NO20090554 L NO 20090554L NO 20090554 A NO20090554 A NO 20090554A NO 20090554 A NO20090554 A NO 20090554A NO 20090554 L NO20090554 L NO 20090554L
Authority
NO
Norway
Prior art keywords
memantine
pharmaceutical preparations
relates
compositions
pharmaceutical
Prior art date
Application number
NO20090554A
Other languages
English (en)
Norwegian (no)
Inventor
Julia Hrakovsky
Hagit Sebban
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NO20090554L publication Critical patent/NO20090554L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20090554A 2006-07-05 2009-02-04 Farmasoytiske preparater av memantin NO20090554L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81882306P 2006-07-05 2006-07-05
PCT/US2006/036628 WO2008005036A1 (fr) 2006-07-05 2006-09-20 Composition pharmaceutique de mémantine

Publications (1)

Publication Number Publication Date
NO20090554L true NO20090554L (no) 2009-02-04

Family

ID=37440592

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090554A NO20090554L (no) 2006-07-05 2009-02-04 Farmasoytiske preparater av memantin

Country Status (12)

Country Link
US (1) US20080008752A1 (fr)
EP (1) EP1886670A1 (fr)
JP (1) JP2009542647A (fr)
KR (1) KR20090016611A (fr)
CN (1) CN101528202A (fr)
BR (1) BRPI0621789A2 (fr)
CA (1) CA2654523A1 (fr)
IL (1) IL195541A0 (fr)
MX (1) MX2008016568A (fr)
NO (1) NO20090554L (fr)
RU (1) RU2009103658A (fr)
WO (1) WO2008005036A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
EP2583669A1 (fr) 2007-10-10 2013-04-24 Rubicon Research Private Limited Comprimés de chlorhydrate de mémantine à dissolution orale et au goût masqué
US20100232659A1 (en) * 2009-03-12 2010-09-16 Harris Corporation Method for fingerprint template synthesis and fingerprint mosaicing using a point matching algorithm
WO2010112221A1 (fr) * 2009-04-03 2010-10-07 Synthon B.V. Compositions pharmaceutiques renfermant de la mémantine
GB0913681D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
US10071059B2 (en) * 2009-12-18 2018-09-11 Frieslandcampina Nederland Holding B.V. Co-processed tablet excipient composition its preparation and use
CA3024216C (fr) * 2010-02-12 2021-03-30 Pfizer Inc. Sels et polymorphes de la 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
TR201001117A1 (tr) 2010-02-15 2011-09-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Dimebolin ve memantin kombinasyonları
RU2483715C2 (ru) * 2010-12-30 2013-06-10 Общество с ограниченной ответственностью "АКАДЕМФАРМ" Твердая лекарственная форма препаратов мемантина и его солей
US20140004189A1 (en) 2011-01-25 2014-01-02 Cadila Healthcare Limited Modified release pharmaceutical compositions memantine
RU2484820C2 (ru) * 2011-02-24 2013-06-20 Общество с ограниченной ответственностью "Озон" Комбинированное лекарственное средство, являющееся ингибитором агрегации тромбоцитов
SG11201401583YA (en) * 2011-10-17 2014-09-26 Lexicon Pharmaceuticals Inc Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
KR101964295B1 (ko) * 2012-09-05 2019-04-01 주식회사 한독 피부 자극이 감소된 메만틴 경피전달 시스템
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
US11241434B2 (en) 2013-06-13 2022-02-08 Yale Uninversity Compositions and methods for improving cognition in a subject
US10660957B2 (en) * 2013-06-13 2020-05-26 Yale University Compositions and methods for treating an Aβ-modulated disease or disorder or improving cognition in a subject
CN104434855B (zh) * 2014-12-10 2017-02-01 哈药集团技术中心 一种盐酸美金刚片及其制备方法
KR101938872B1 (ko) 2016-09-30 2019-01-16 주식회사 바이오파마티스 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법
CN107334744B (zh) * 2017-07-24 2020-09-04 湖南洞庭药业股份有限公司 盐酸美金刚药物组合物和制法
JP7250305B2 (ja) * 2018-10-02 2023-04-03 共和薬品工業株式会社 メマンチン又はその薬物学的に許容される塩を含む医薬組成物及びその製造方法
WO2020075024A1 (fr) * 2018-10-12 2020-04-16 Dr. Reddy’S Laboratories Limited Procédé de préparation de mémantine
US12133918B2 (en) 2021-10-01 2024-11-05 Griffin Gamma, Llc Partially pre-gelatinized cassava starch as pharmaceutical excipient
CN114681423B (zh) * 2022-05-19 2024-02-27 海南林恒制药股份有限公司 一种盐酸美金刚片及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
JP2006527774A (ja) * 2003-06-16 2006-12-07 アラーガン、インコーポレイテッド メマンチン経口製剤
CA2554959A1 (fr) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combinaison d'antagoniste de recepteur nmda et d'inhibiteur mao ou gadpf pour le traitement d'affections liees au systeme nerveux central
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
JP2006138227A (ja) * 2004-11-10 2006-06-01 Toyota Motor Corp 排ガス浄化装置
BRPI0518483A2 (pt) * 2004-11-23 2008-11-18 Neuromolecular Pharmaceuticals Inc composiÇço compreendendo uma matriz ou revestimento de liberaÇço controlada e um antagonista de receptor de nmda, mÉtodo para administraÇço de tal antagonista de nmda a um paciente
CA2588296A1 (fr) * 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition et methode pour traiter des affections neurologiques
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US7462743B2 (en) * 2005-01-11 2008-12-09 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of memantine hydrochloride
BRPI0607017B8 (pt) * 2005-04-06 2021-05-25 Adamas Pharmaceuticals Inc composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
EA013474B1 (ru) * 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
EP2040676A2 (fr) * 2006-07-06 2009-04-01 Forest Laboratories, Inc. Formulations à dissolution orale de mémantine

Also Published As

Publication number Publication date
BRPI0621789A2 (pt) 2012-05-02
IL195541A0 (en) 2009-09-01
EP1886670A1 (fr) 2008-02-13
US20080008752A1 (en) 2008-01-10
CA2654523A1 (fr) 2008-01-10
RU2009103658A (ru) 2010-08-10
WO2008005036A1 (fr) 2008-01-10
CN101528202A (zh) 2009-09-09
JP2009542647A (ja) 2009-12-03
KR20090016611A (ko) 2009-02-16
MX2008016568A (es) 2009-01-19

Similar Documents

Publication Publication Date Title
NO20090554L (no) Farmasoytiske preparater av memantin
TW200711652A (en) Method and composition for pharmaceutical product
JOP20180109A1 (ar) تركيبة جديدة
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
MY147641A (en) Fast release paracetamol tablets
JO3406B1 (ar) عملية لتصنيع منتج صيدلاني يشتمل على حمض الستريك ،أكسيد ماغنسيوم، بيكربونات بوتاسيوم وبيكو كبريتات صوديوم، تركيبة صيدلانية تشتمل على حبيبات متحصل عليها بواسطة هذه العملية ومنتجات وسيطة منها
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
UA93353C2 (ru) Производство фармацевтических композиций c быстрым высвобождением ha ochobe водонерастворимых лекарсвенных средств и фармацевтические композиции, полученные способом согласно изобретению
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
WO2009032843A3 (fr) Aminoalcools substitués
HK1214519A1 (zh) 雙用途硫酸鹽口服藥物組合物片劑及其使用方法
NO20070187L (no) Oralt desintegrerende farmasoytisk preparat omfattende risperidon
NO20076120L (no) Stabile nanopartikkelformuleringer
WO2009084036A3 (fr) Composition utilisée pour traiter les infections virales
IL191670A0 (en) Compounds for the inhibition of apoptosis
IL191992A0 (en) Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
DK1979321T3 (da) Nye pyridinylaminoalkylen- og pyridinyloxyalkylen-cyclopropanaminer, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende dissse
DK1742927T3 (da) Butanonsyrederivater, fremgangsmåder til fremstilling deraf, farmaceutiske præparater omfattende dem, og farmaceutiske applikationer deraf
DK1707564T3 (da) Indanyl-piperazinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
WO2012068076A3 (fr) Formulations pharmaceutiques contenant des médicaments solubles
DK1818048T3 (da) Farmaceutiske formuleringer af alifatiske aminpolymerer og metoder til deres fremstilling
GB0615105D0 (en) Novel compounds
MX374707B (es) Comprimidos de ibuprofeno de sodio y procedimientos de fabricacion de composiciones farmaceuticas que incluyen ibuprofeno de sodio.
GB0620619D0 (en) Novel compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application